Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 17, 2016

Deals this week: Pfizer, Peakdale Molecular, Selexis

Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple cancers.

Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple cancers.

Under the terms of the agreement, the two partners will jointly conduct pre-clinical and clinical trials to examine the efficacy of Pfizer’s proprietary investigational immunotherapy agents.

The agreement enables the partners to study the three immunotherapy agents in combination with standard therapies such as chemotherapy, radiation and targeted therapies to treat a range of cancers.

Peakdale Molecular has made an agreement with Metrion Biosciences to create drug discovery programmes for the customers for ion channel targets.

"The agreement enables the two partners to offer integrated drug discovery services."

The agreement enables the two partners to offer integrated drug discovery services to pharmaceutical and biotechnology companies.

Selexis and OSE Immunotherapeutics have entered an contract to further develop immunotherapy agents targeting cancer and autoimmune diseases.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

According to the agreement, Selexis’ proprietary SURE technology platform will be utilised to access performance research cell banks (RBCs) and advance the development of OSE Immunotherapuetics’ pre-clinical products.

Pfizer plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes due 2046.

Skadden, Aprs, Slate, Meagher & Flom is acting as the legal adviser for the offering.

Pfizer plans to use the funds to purchase the tender notes, for general corporate purposes and also to repay its outstanding commercial paper.

Tonghua Golden Horse Pharmaceutical Industry plans for the public offering of bonds. The company expects to raise up to $219m from the offering.


Image: Pfizer Inc plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU